About BroadenBio

About BroadenBio

——

Team

图片名称

Team

previous page

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor effective in multiple xenograft tumor models

BroadenBio Announces First Patient Enrollment in Phase I Study of HPK1 inhibitor BB3008

next page

previous page

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor effective in multiple xenograft tumor models

next page

BroadenBio Announces First Patient Enrollment in Phase I Study of HPK1 inhibitor BB3008

address：

A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176

phone：

e-mail：

hr@broadenbio.com

Copyright ©2019 BroadenBio

Powered by www.300.cn

business license